Top

American Journal of Clinical Dermatology

Published in:

01-08-2015 | Adis Drug Evaluation

Secukinumab: A Review in Moderate to Severe Plaque Psoriasis

Author: Karly P. Garnock-Jones

Published in: American Journal of Clinical Dermatology | Issue 4/2015

Abstract

Secukinumab (Cosentyx™) is a fully human monoclonal immunoglobulin G1κ antibody targeting human interleukin-17A, an important cytokine in the pathogenesis of psoriasis. Secukinumab, as well as being first in its drug class, is the first biologic treatment to be approved in the EU for the first-line systemic treatment of moderate to severe plaque psoriasis. This article reviews the pharmacologic properties of secukinumab and its clinical efficacy and tolerability in adult patients with moderate to severe plaque psoriasis. In clinical trials, subcutaneous secukinumab was more effective than placebo, etanercept and ustekinumab at improving both psoriasis symptoms (with high skin clearance) and health-related quality of life. Moreover, secukinumab was more effective than placebo in the difficult-to-treat palmoplantar and nail psoriasis populations. Secukinumab was generally well tolerated, with low immunogenicity. Longer-term, efficacy was sustained and secukinumab remained well tolerated. Subcutaneous secukinumab is an effective and generally well tolerated first-line treatment for moderate to severe plaque psoriasis, and is a useful addition to the treatment options for this disease.

Gisondi P, Dalle Vedove C, Girolomoni G. Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy. Dermatol Ther. 2014;4(1):1–9.CrossRef

Adami S, Cavani A, Rossi F, et al. The role of interleukin-17A in psoriatic disease. BioDrugs. 2014;28(6):487–97.PubMedCrossRef

Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(Suppl. 2):1–70.PubMedCrossRef

Novartis Europharm Limited. Cosentyx™ (secukinumab subcutaneous injection): EU summary of product characteristics. 2015. http://www.ema.europa.eu. Accessed 18 Jun 2015.

Lynde CW, Poulin Y, Vender R, et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141–50.PubMedCrossRef

Novartis Pharmaceuticals Corporation. Cosentyx™ (secukinumab subcutaneous injection): US prescribing information. 2015. http://www.pharma.us.novartis.com. Accessed 18 Jun 2015.

Novartis Pharmaceuticals Corporation. Advisory Committee briefing materials: secukinumab. 2014. www.fda.gov. Accessed 18 Jun 2015.

Kolbinger F, Bruin G, Valentin MA, et al. Secukinumab treatment rapidly leads to positive proteomic and transcriptional changes in psoriatic skin [abstract no. P1656]. In: 23rd congress of the European Academy of Dermatology and Venereology. 2014.

Krueger J, Wharton K, Fuentes-Duculan J, et al. Secukinumab reverses disease-defining psoriasis histopathology while retaining full T-cell activation potential [abstract no. P43]. Br J Dermatol. 2014;171:e140.

10.

Reich K, Papp KA, Matheson RT, et al. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Exp Dermatol. 2015. doi:10.1111/exd.12710.PubMed

11.

Bruin G, Dragatin C, Aigner B, et al. Secukinumab, a novel anti-IL-17A antibody, can be quantified in skin after a single dose by dermal open flow microperfusion (dOFM) [abstract]. J Dtsch Dermatol Ges. 2014;12(Suppl 1):15.

12.

Gottlieb A, Sigurgeirsson B, Blauvelt A, et al. Secukinumab reduces hsCRP levels in subjects with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis: a sub-analysis from the phase 3 ERASURE study [abstract no. AB0738]. Ann Rheum Dis. 2014;73(Suppl 2):1047.CrossRef

13.

Strober B, Guettner A, Sigurgeirrson B, et al. Secukinumab reduces C-reactive protein levels in patients with moderate to severe plaque psoriasis: result of a regimen-finding study [abstract no. P6395]. J Am Acad Dermatol. 2013;68(4 Suppl 1):AB212.

14.

Mrowietz U, Qureshi A, Escrig C. Secukinumab treatment shows a neutral effect on the lipid profile of patients with moderate to severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled, phase II study [abstract no. P6871]. J Am Acad Dermatol. 2013;68(4 Suppl 1):AB212.

15.

Chioato A, Noseda E, Stevens M, et al. Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study. Clin Vaccine Immunol. 2012;19(10):1597–602.PubMedCentralPubMedCrossRef

16.

US FDA. Dermatologic and Ophthalmic Drugs Advisory Committee Meeting background package for BLA 125504 Cosentyx (secukinumab). 2014. http://www.fda.gov. Accessed 18 Jun 2015.

17.

Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168(2):402–11.PubMedCrossRef

18.

Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412–21.PubMedCrossRef

19.

Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38.PubMedCrossRef

20.

Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2014;172(2):484–93.PubMedCrossRef

21.

Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2014;29(6):1082–90.PubMedCrossRef

22.

Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015. doi:10.1016/j.jaad.2015.05.013.

23.

Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab efficacy and safety in subjects with moderate to severe palmoplantar psoriasis in a phase 3b study (GESTURE) [abstract no. FC24-07]. In: 23rd World Congress of Dermatology. 2015.

24.

Reich K, Sullivan J, Arenberger P, et al. Secukinumab is effective in subjects with nail psoriasis: 16 week results from the TRANSFIGURE study [abstract]. In: 23rd World Congress of Dermatology. 2015.

25.

Papp K, Karpov A, Papavassilis C, et al. Secukinumab efficacy in relationship with response to previous biologic psoriasis therapy: a subanalysis from the ERASURE Study [abstract no. P8011]. J Am Acad Dermatol. 2014;70(5 Suppl 1):AB186.

26.

Blauvelt A, Gottlieb A, Sigurgeirsson B, et al. Secukinumab efficacy in subjects with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis: a subanalysis of the ERASURE study [abstract no. P8033]. J Am Acad Dermatol. 2014;70(5 Suppl 1):AB2.

27.

Philipp S, Papavassilis C, Notter M, et al. Secukinumab effect on functional ability in subjects with moderate to severe plaque psoriasis and psoriatic arthritis: a subanalysis from the FIXTURE study [abstract no. P8098]. J Am Acad Dermatol. 2014;70:AB185.

28.

Blauvelt A, Szepietowski J, Sigurgeirrson B, et al. Secukinumab treatment maintains efficacy in moderate to severe plaque psoriasis through second year of treatment: a randomized extension of the ERASURE and FIXTURE studies [abstract]. In: 73rd annual meeting of the American Academy of Dermatology. 2015.

29.

Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1):27–36 e1.

30.

Thaci D, Humeniuk J, Frambach Y, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015. doi:10.1111/bjd.13814.

31.

Tsai T, Blauvelt A, Karpov A, et al. Evaluation of infections with secukinumab in a pooled analysis of 10 clinical studies of moderate-to-severe plaque psoriasis [abstract no. 193]. J Invest Dermatol. 2014;134:S33.CrossRef

32.

Griffiths C, Guettner A, Prinz J, et al. Secukinumab safety in subjects with moderate to severe plaque psoriasis: a pooled analysis of neutropenia from 10 clinical studies [abstract no. P8266]. J Am Acad Dermatol. 2014;70(5 Suppl 1):AB188.

33.

Van De Kerkhof P, Strober B, Karpov A, et al. Evaluation of malignancy risk with secukinumab treatment in a pooled analysis of 10 clinical studies of moderate-to-severe plaque psoriasis up to 52 weeks [abstract no. 194]. J Invest Dermatol. 2014;134:S33.CrossRef

34.

Craig L, Nehal M, Mark L, et al. Incidence of major adverse cardiovascular events with secukinumab: a pooled analysis of data from 10 phase 2 and 3 clinical trials in psoriasis [abstract no. T.106]. In: Federation of Clinical Immunology Societies Annual Meeting. 2014.

35.

Ward N, Guettner A, Sands B, et al. Secukinumab safety and tolerability in subjects with moderate to severe plaque psoriasis: a pooled subgroup analysis of 10 clinical studies evaluating exacerbation of Crohn’s disease [abstract no. P8233]. J Am Acad Dermatol. 2014;70(5 Suppl 1):AB188.

36.

Reich K, Blauvelt A, Armstrong A, et al. Secukinumab, a novel Anti-IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro assays [abstract no. 1320]. In: 73rd annual meeting of the American Academy of Dermatology. 2015.

37.

Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148(1):95–102.PubMedCrossRef

38.

Handa S. Newer trends in the management of psoriasis at difficult to treat locations: scalp, palmoplantar disease and nails. Indian J Dermatol Venereol Leprol. 2010;76(6):634–44.PubMedCrossRef

39.

Sanford M, McKeage K. Secukinumab: first global approval. Drugs. 2015;75(3):329–38.PubMedCrossRef

Title: Secukinumab: A Review in Moderate to Severe Plaque Psoriasis
Author: Karly P. Garnock-Jones
Publication date: 01-08-2015
Publisher: Springer International Publishing
Published in: American Journal of Clinical Dermatology / Issue 4/2015
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-015-0143-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Secukinumab: A Review in Moderate to Severe Plaque Psoriasis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2015

Cellulite: An Evidence-Based Review

Comparison of Systemic Mycophenolate Mofetil with Topical Clobetasol in Lichen Planopilaris: A Parallel-Group, Assessor- and Analyst-Blinded, Randomized Controlled Trial

Resource Use and Costs in an Insured Population of Patients with Chronic Idiopathic/Spontaneous Urticaria

23rd World Congress of Dermatology: Vancouver, Canada, June 8–13, 2015

Poland’s Syndrome: A Concise Review of the Clinical Features Highlighting Associated Dermatologic Manifestations

Immunogenicity of Biologic Treatments for Psoriasis: Therapeutic Consequences and the Potential Value of Concomitant Methotrexate